ArticleNature nanotechnology2019
Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies.
Article in Nature nanotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The microbiome-nitric oxide axis in cancer immunotherapy: a targeted qualitative systematic review of mechanistic and translational evidence.Frontiers in immunology · 2026Pooled it
- Metabolic regulation and immunosuppressive functions of lipid-associated macrophages in pancreatic ductal adenocarcinoma.Frontiers in immunology · 2026Pooled it
- Red light-mediated stepwise nitric oxide releaseChemical science · 2026Article
- Catalytic Nitric Oxide-Generating Selenium Nanoparticle-Loaded Hydrogels With Anti-Inflammatory and Pro-Wound-Healing Properties.Small science · 2026Article
- NO-PDT and chemotherapy: spatiotemporal control to achieve therapeutic synergy.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Review
- Single-pore silica nanotherapeutic platform with pH-Responsive NO release for osteoporosis repair.Materials today. Bio · 2026Article
- An engineered E. coli strain sustains intratumoral nitric oxide production to boost effectiveness of tumor immunotherapy.Nature biotechnology · 2026Article
- Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy.Nature biotechnology · 2026Article
- Leveraging vascular normalizationActa pharmaceutica Sinica. B · 2026Article
- Nitrogen-Boosted HAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Exploiting eNOS activation to achieve tumor vascular normalizationActa pharmaceutica Sinica. B · 2026Article
- Cascade-driven nanomotor with self-amplifying necrosis targeting and deep tumor penetration for enhanced type I photodynamic immunotherapy.Materials today. Bio · 2026Article
- Gasotransmitters bridging tumor biology and immunity: from pathophysiological insights to therapeutic potential.Frontiers in immunology · 2026Review
- Nanotechnology-Enabled Diagnosis and Treatment of Hepatocellular Carcinoma: Theranostics, Combination Regimens, and Translation.International journal of nanomedicine · 2026Review
- Nanozymes in Tumor Microenvironment Modulation for Cancer Therapy.Biomaterials research · 2026Review
- Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance.Frontiers in oncology · 2026Review
- NIR-Propelled Biomimetic Nanomotors for Photothermal/Chemodynamic/NO Synergistic Tumor Therapy.Cyborg and bionic systems (Washington, D.C.) · 2026Article
- Nano-Immunotherapy Synergizing Ferroptosis and STING Activation in Metastatic Bladder Cancer.Cyborg and bionic systems (Washington, D.C.) · 2026Article
- Microneedle Mediated Gas Delivery for Rapid Separation, Enhanced Drug Penetration, and Combined Therapy.Pharmaceutics · 2025Review
- Overcoming chemoresistance via NO-mediated HSP inhibition using hybrid membrane-coated multifunctional nanoplatforms.Materials today. Bio · 2025Article
72 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abnormal tumour vasculature has a significant impact on tumour progression and response to therapy. Nitric oxide (NO) regulates angiogenesis and maintains vascular homeostasis and, thus, can be delivered to normalize tumour vasculature. However, a NO-delivery system with a prolonged half-life and a sustained release mechanism is currently lacking. Here we report the development of NanoNO, a nanoscale carrier that enables sustained NO release to efficiently deliver NO into hepatocellular carcinoma. Low-dose NanoNO normalizes tumour vessels and improves the delivery and effectiveness of chemotherapeutics and tumour necrosis factor-related, apoptosis-inducing, ligand-based therapy in both primary tumours and metastases. Furthermore, low-dose NanoNO reprogrammes the immunosuppressive tumour microenvironment toward an immunostimulatory phenotype, thereby improving the efficacy of cancer vaccine immunotherapy. Our findings demonstrate the ability of nanoscale NO delivery to efficiently reprogramme tumour vasculature and immune microenvironments to overcome resistance to cancer therapy, resulting in a therapeutic benefit.
Indexed as
Identifiers
31740794What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.